Analysts have provided the following estimates for Gilead Sciences (NASDAQ:GILD) for the most recent quarter.
Trending. An entrepreneur makes $175,000 a year selling T-shirts he never touches, working just an hour a day;
Must read. Mark Cuban says it's the key to "controlling your own destiny" and making big bucks
| bullish | pretty intense | Indifferent | a bit irrelevant | Carry | |
|---|---|---|---|---|---|
| overall ratings | 1: | 2: | 6:00 a.m | 0: | 0: |
| last 30 days | 0: | 0: | 1: | 0: | 0: |
| 1 million ago | 0: | 0: | 0: | 0: | 0: |
| 2 months ago | 1: | 0: | 1: | 0: | 0: |
| 3 months ago | 0: | 2: | 4: | 0: | 0: |
Based on 9 analysts providing 12-month price targets over the last 3 months, Gilead Sciences has an average price target of $92.33, with a high of $112.00 and a low of $80.00.
Below is a summary of how these 9 analysts rated Gilead Sciences over the last 3 months. The higher the number of ratings, the more analysts rate the stock positively, and the higher the number of downgrades, the more analysts rate the stock negatively.
© Provided by Benzinga Target price chart
This current average is 5.32% above the previous average price target of $87.67.
Stay informed with Gilead Sciences analyst notes.
Ratings are derived from banking and financial systems analysts or professionals reporting on specific securities or specific sectors (usually quarterly for each security). Analysts typically get their information from company conference calls and meetings, financial reports, and discussions with people important to their decision-making.
Some analysts also offer forecasts for utility metrics such as earnings, revenue, and growth estimates to provide further guidance on what to do with specific metrics. It's important to note that while stock and industry analysts are experts, they are human and can only guess their opinions to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest GILD ratings
| Date: | Business | Action: | starting | For |
|---|---|---|---|---|
| March 2022 | barley | holds | underweight | |
| March 2022 | RBC capital | holds | Overcome | |
| February 2022 | BMO capital: | sale | Overcome | market trend |
See additional analyst notes on GILD
Check out the latest analyst ratings
© 2023 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
This article on Gilead Sciences Expert Reviews originally appeared on Benzinga.com
.